



# MD Anderson at the 2021 AACR Virtual Meeting

Week I : April 10-15, 2021

THE UNIVERSITY OF TEXAS  
**MDAnderson**  
~~Cancer~~ Center  
Making Cancer History®

<b>LIVE PRESENTATIONS</b>			
<b>Saturday, April 10</b>			
<b>1:30-3:30 p.m. EDT</b>	<b>21-LB-5330-AACR: Clinical Trials Minisymposium</b> Early Clinical Trials with New Anticancer Agents	CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a Phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16)	<b>Sarina Piha-Paul, M.D.</b>
<b>1:30-3:30 p.m. EDT</b>	<b>21-A-3956-AACR: Minisymposium</b> Biomarkers	22: A novel, inflamed small cell lung cancer transcriptional subtype, SCLC-I, defines a subset of patients with distinct immunotherapy vulnerability	<b>Carl Gay, M.D., Ph.D.</b>
<b>1:30-3:30 p.m. EDT</b>	<b>21-A-2708-AACR: Minisymposium</b> Overcoming Resistance in the Tumor Microenvironment: Novel Immunotherapy Agents	76: TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice	<b>Ismail M. Meraz, Ph.D.</b>
<b>4:00-6:00 p.m. EDT</b>	<b>21-A-2143-AACR: Minisymposium</b> Redefining the Tumor Microenvironmental Vulnerability with Single Cell Technologies	130: Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing	<b>Ansam Sinjab</b>
<b>4:00-6:00 p.m. EDT</b>	<b>21-A-3058-AACR: Minisymposium</b> Cell Growth Signaling Pathways	83: Structural and biochemical properties of DIRAS3 N-terminal extension that permit its function as a tumor suppressor of oncogenic K-RAS	<b>Xiaowen Liang, Ph.D.</b>
<b>4:00-6:00 p.m. EDT</b>	<b>21-A-4150-AACR: Minisymposium</b> Redefining the Tumor Microenvironmental Vulnerability with Single Cell Technologies	132: Spatial analyses reveal differential immune cell interactions in human gliomas and brain metastasis based on STAT3 expression	<b>Martina Ott, Ph.D.</b>

<b>Sunday, April 11</b>			
<b>2:00-3:45 p.m. EDT</b>	<b>21-LB-4939-AACR:</b> <b>Clinical Trials</b> <b>Plenary Session</b> Targeted Therapy and Ovarian Cancer Trials	CT011: Efficacy and Safety of Selpercatinib in RET Fusion-Positive Cancers Other than Lung or Thyroid Cancers	<b>Vivek Subbiah, M.D.</b>
<b>2:00-3:45 p.m. EDT</b>	<b>SS02 NextGen Stars</b> <b>Spotlight Session: Tumor</b> Microenvironment, Metastasis, and Oncogenesis	NG07 - Cancer takes a nerve: Loss of p53 drives neuron reprogramming in head and neck cancer	<b>Moran Amit, Ph.D.</b>
<b>2:00-4:00 p.m. EDT</b>	<b>21-LB-5197-AACR:</b> <b>Clinical Trials</b> <b>Minisymposium</b> Molecular Targeted Agents in the Clinic	CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)	<b>Vivek Subbiah, M.D.</b>
<b>2:00-4:00 p.m. EDT</b>	<b>21-A-4232-AACR:</b> <b>Minisymposium</b> Metabolic Pathways in Cancer	87: Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis	<b>Nakia Spencer</b>
<b>2:00-4:00 p.m. EDT</b>	<b>21-A-1362-AACR:</b> <b>Minisymposium</b> Developing and Applying Preclinical Cancer Models	120: Compartmentalized functions of epidermal growth factor receptor (EGFR) in tumorigenesis and malignant phenotypes	<b>Lei Nie, M.D.</b>
<b>2:00-4:00 p.m. EDT</b>	<b>21-A-3685-AACR:</b> <b>Minisymposium</b> Mapping the Cellular and Molecular Cues That Control Therapeutic Antitumor Immunity	70: Obesity-induced impairment of antitumor immunity is associated with an immunosuppressive tumor immune landscape	<b>Barbara Pazdra, M.D.</b>

## Monday, April 12

<p><b>1:30-3:30 p.m. EDT</b></p>	<p><b>21-LB-5237-AACR: Late-Breaking Minisymposium</b> Late-Breaking Minisymposium 2</p>	<p>LB008: Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC)</p>	<p><b>Yifei Wang</b></p>
<p><b>1:30-3:30 p.m. EDT</b></p>	<p><b>21-A-4108-AACR: Minisymposium</b> Advancing Cancer Research Through An International Cancer Registry: AACR Project GENIE Use Cases</p>	<p>103: Spatially resolved transcriptomics identified distinct tumor-stroma crosstalk networks in long term ovarian cancer survivors</p>	<p><b>Sammy Ferri-Borgogno</b></p>

<b>ON-DEMAND VIRTUAL POSTER PRESENTATIONS</b>		
21-LB-5457-AACR: Poster Session – Combination Immunotherapies	LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study	<b>Filip Janku, M.D., Ph.D.</b>
21-LB-4954-AACR: Poster Session – Phase I Clinical Trials	CT105: Preliminary safety and efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T cell receptor fusion construct (TRuC™), in patients with treatment refractory mesothelin overexpressing solid tumors	<b>David Hong, M.D.</b>
21-LB-5360-AACR: Poster Session – Liquid Biopsies: Circulating DNA	LB057: Whole exome sequencing of tumor tissue and circulating tumor DNA in gastrointestinal stromal tumors (GIST)	<b>Niamh Coleman, M.D., Ph.D.</b>
21-LB-5417-AACR: Poster Session – Biological Therapeutic Agents	LB097: MET inhibitor enhances efficacy of gemcitabine and olaparib in pancreatic cancer cells	<b>Mei-Kuang Chen</b>
21-LB-5033-AACR: Poster Session – Phase I Trials in Progress	CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF	<b>Filip Janku, M.D., Ph.D.</b>
21-LB-5016-AACR: Poster Session – Phase I Clinical Trials	CT109: Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxel in patients with advanced solid malignancies and mTOR pathway alterations	<b>Omar Alhalabi, M.D.</b>
21-LB-5018-AACR: Poster Session – Phase I Clinical Trials	CT110: Intratumoral injection of SYN1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation	<b>Filip Janku, M.D., Ph.D.</b>
21-LB-5077-AACR: Poster Session – Pediatric Cancer: Basic Science	LB252: Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models	<b>Douglas Harrison, M.D.</b>

<p><b>21-LB-5504-AACR: Poster Session –</b> Clinical Prevention, Early Detection, and Interception</p>	<p>LB223: Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects: First results from the BE GONE Trial in high-risk colorectal patients</p>	<p><b>Carrie Daniel-MacDougall, Ph.D.</b></p>
<p><b>21-LB-5241-AACR: Poster Session –</b> Phase II Clinical Trials</p>	<p>CT174: Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma</p>	<p><b>Michael Lee, M.D.</b></p>
<p><b>21-LB-5303-AACR: Poster Session –</b> Metabolic Pathways</p>	<p>LB208: Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM)</p>	<p><b>Andrew Hahn, M.D.</b></p>
<p><b>21-LB-6091-AACR: Poster Session – Drug</b> Resistance in Molecular Targeted Therapies</p>	<p>LB264: Oncogenic KRAS<sup>G12C</sup> dependency in colorectal cancer</p>	<p><b>Oluwadara Coker</b></p>
<p><b>21-LB-576-AACR: Poster Session - Phase</b> II Clinical Trials</p>	<p>CT169: Pozotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)</p>	<p><b>Xiuning Le, M.D., Ph.D.</b></p>
<p><b>21-LB-5254-AACR: Poster Session –</b> Cell Cycle</p>	<p>LB185: BBX and PLK1 feedback mechanisms regulate mitotic entry &amp; exit</p>	<p><b>Gaiyun Li, Ph.D.</b></p>
<p><b>21-A-1757-AACR: Poster Session –</b> Preclinical Prevention, Early Detection, and Interception</p>	<p>2592: Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer</p>	<p><b>Yuan Zhang</b></p>
<p><b>21-A-4198-AACR: Poster Session –</b> Preclinical Radiotherapies</p>	<p>1389: Bismuth gadolinium nanoparticles enhance radiation therapy in hepatocellular carcinoma</p>	<p><b>Avinash Kakulavar</b></p>

21-A-928-AACR: Poster Session – Drug Resistance in Molecular Targeted Therapies	1112: Exploiting oncogene-conferred glutamine addiction as a therapeutic vulnerability in resistant mantle cell lymphoma	<b>Lingzhi Li</b>
21-A-1128-AACR: Poster Session – Immune Cells in the Tumor Microenvironment	2744: The immune landscape of recurrent ovarian carcinoma	<b>Han Cun, M.D.</b>
21-A-1220-AACR: Poster Session – Metabolic Pathways	2322: Targeting glutamine transporter (ASCT2) inhibits metabolic stress-induced GD2 <sup>+</sup> cancer stem cell-like phenotype in triple-negative breast cancer	<b>Appalaraju Jaggupilli</b>
21-A-1370-AACR: Poster Session – Epigenetic Regulation of Tumor Immunity	1599: SMARCA4 regulates tumor resistance to anti-tumor immune response	<b>Appoorvi Chaudhri</b>
21-A-1597-AACR: Poster Session – Transcription Factor Function	2477: Regulation and function of ZEB1 dimerization in lung adenocarcinoma progression and metastasis	<b>Mabel Perez-Oquendo</b>
21-A-1659-AACR: Poster Session – Preclinical Prevention, Early Detection, and Interception	2563: Endometrial organoids derived from mismatch repair-deficient mice have attenuated progesterone response compared to wild-type organoids	<b>Mikayla Waters</b>
21-A-1751-AACR: Poster Session – Biomarkers Predictive of Therapeutic Benefit	392: Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay	<b>Amber Johnson, Ph.D.</b>
21-A-1794-AACR: Poster Session – Immunity and the Tumor Microenvironment	2794: Blocking histamine receptor H1 on macrophages with anti-allergy drugs restores T-cell anti-tumor immunity	<b>Yi Xiao, Ph.D.</b>

<p><b>21-A-2155-AAACR: Poster Session – COVID-19 and Cancer</b></p>	<p>702: Single-cell expression landscape of SARS-CoV-2 receptor ACE2 and host proteases in human lung adenocarcinoma</p>	<p><b>Guangchun Han</b></p>
<p><b>21-A-2162-AAACR: Poster Session – Human-in-Mouse Models of Human Cancer</b></p>	<p>2710: The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers</p>	<p><b>Timothy DiPeri</b></p>
<p><b>21-A-2375-AAACR: Poster Session – Patient-Derived Xenograft Models</b></p>	<p>3009: A systemic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers</p>	<p><b>Dali Li</b></p>
<p><b>21-A-2658-AAACR: Poster Session – Biomarkers Predictive of Therapeutic Benefit</b></p>	<p>368: Aurora kinase inhibitors cause cell death in HPV+ cells: A plausible treatment option for HPV+ cancers</p>	<p><b>Tuhina Mazumdar, Ph.D.</b></p>
<p><b>21-A-2777-AAACR: Poster Session – Molecular Classification of Tumors/Tumor Staging</b></p>	<p>619: Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naïve resected NSCLC</p>	<p><b>Neal Akhave, M.D.</b></p>
<p><b>21-A-2992-AAACR: Poster Session – Microbiome</b></p>	<p>2906: Retrospective analyses of sequencing datasets suggest that intratumoral microbes exist in metastatic brain tumors</p>	<p><b>Golnaz Morad</b></p>
<p><b>21-A-3041-AAACR: Poster Session – Cell Death Pathways and Treatment</b></p>	<p>985: BI 905711 selectively induces apoptosis and anti-tumor response in TRAILR2/CDH17- expressing pancreatic cancer models</p>	<p><b>Jing Han, Ph.D.</b></p>
<p><b>21-A-3136-AAACR: Poster Session – Adoptive Cell Therapy</b></p>	<p>1489: Deposition of genetically engineered T cell attracting antigen presenting cells in the glioma microenvironment with low intensity pulsed ultrasound-based blood-brain barrier opening triggers therapeutic responses in preclinical glioma models</p>	<p><b>Aria Sabbagh</b></p>



<p><b>21-A-3454-AACR: Poster Session –</b> Modifiers of the Tumor Microenvironment</p>	<p>1786: Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy</p>	<p><b>Sagar Sohoni</b></p>
<p><b>21-A-3667-AACR: Poster Session –</b> Cellular Responses to Anticancer Drugs</p>	<p>1022: Characterization of lurbinectedin as a single agent and in combinations with DNA damage response inhibitor for the treatment and bio-marker discovery of SCLC</p>	<p><b>Kiran Kundu, Ph.D.</b></p>
<p><b>21-A-3872-AACR: Poster Session –</b> Immune Cells in the Tumor Microenvironment</p>	<p>2758: Multiplex immunofluorescence (mIF) reveals differences in tumor immune microenvironment between molecularly-defined subsets of small cell lung cancer</p>	<p><b>Pedro Rocha</b></p>
<p><b>21-A-4038-AACR: Poster Session –</b> Functional Genomics</p>	<p>2316: Diversity across the pancreatic ductal adenocarcinoma disease spectrum revealed by network-anchored functional genomics</p>	<p><b>Sanjana Srinivasan</b></p>
<p><b>21-A-4078-AACR: Poster Session – Liquid Biopsies: Circulating DNA</b></p>	<p>575: Enhancing cell-free DNA mutation detection with novel liquid-phase extraction</p>	<p><b>Filip Janku, M.D., Ph.D.</b></p>
<p><b>21-A-4146-AACR: Poster Session –</b> Biomarkers of Prognosis</p>	<p>770: High-grade neuroendocrine carcinoma of the oropharynx: A rare entity with prognosis unaffected by HPV</p>	<p><b>Luana Sousa, M.D.</b></p>
<p><b>21-A-4543-AACR: Poster Session –</b> Cellular Stress Responses</p>	<p>2028: The unfolded protein response as a therapeutic target in endometrial cancer</p>	<p><b>Mikayla Waters</b></p>
<p><b>21-A-4566-AACR: Poster Session –</b> Epigenetics</p>	<p>2129: Usp22 controls multiple signaling pathways in development and disease</p>	<p><b>Evangelia Koutelou, Ph.D.</b></p>

21-A-3445-AACR: Poster Session – Immunomodulatory Agents and Interventions	521: Osteopontin-targeting aptamers exert therapeutic activity in vivo against lung cancer	<b>Jun Wei, Ph.D.</b>
21-A-1961-AACR: Poster Session – Stem Cell Biology	3110: ICAM-1(CD54) mediated bi-lineage differentiation in osteosarcoma	<b>Sankaranarayanan Kannan, DPHIL</b>
21-A-4242-AACR: Poster Session – Nuclear Oncoproteins, Oncogenes, and Tumor Suppressor Genes	2411: CEACAM1 is a Critical SOX9-regulated gene that suppresses TNBC growth	<b>Yanxia Ma, Ph.D.</b>
21-A-909-AACR: Poster Session – Tumor-Immune System Interactions	3174: Spatial immune cell and transcriptome profiling of tumors from primary and metastatic sites in advanced uterine serous carcinoma patients	<b>Li Zhang</b>
21-A-974-AACR: Poster Session – Immunomodulatory Agents and Interventions	1705: Identification and validation of neoantigens for developing a preventive vaccine for mismatch-repair deficient cancers	<b>Charles Bowen</b>
21-A-1190-AACR: Poster Session – Genomic Profiling of Tumors	2200: NF1 copy number alterations in clinically-defined subsets of high-grade serous ovarian cancers	<b>Sanghoon Lee, Ph.D.</b>
21-A-1652-AACR: Poster Session – Stem Cell Biology	3077: ATRX <sup>Loss</sup> and IDH1 <sup>R132H</sup> impair self-renewal of glioma stem cells after proton radiotherapy	<b>Ángel Adrian Garcés</b>
21-A-1904-AACR: Poster Session – Invasion and Metastasis 1	2844: The role of oxidative phosphorylation (OXPHOS) in melanoma brain metastasis (MBM) formation and growth	<b>Renato Guerrieri</b>

21-A-2003-AACR: Poster Session – Drug Resistance in Molecular Targeted Therapies	1102: Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors	<b>Jeffrey Kovacs, Ph.D.</b>
21-A-2404-AACR: Poster Session – Liquid Biopsies: Circulating DNA	564: BRAF <sup>V600</sup> mutation in circulating tumor DNA can predict outcomes in early-stage melanoma	<b>Mohamed Gouda</b>
21-A-2531-AACR: Poster Session – Metabolomics	2346: Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel	<b>Estefania Labanca</b>
21-A-2653-AACR: Poster Session – Cell Signaling	1999: DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas	<b>Gamze Bildik</b>
21-A-2729-AACR: Poster Session – Biomarkers Predictive of Therapeutic Benefit	369: Identification of pathways that enhance cell death in NOTCH1-mutant HNSCC	<b>Pooja Shah</b>
21-A-2746-AACR: Poster Session – Modifiers of the Tumor Microenvironment	1785: Inhibition of the IDO-Kyn-AhR cascade optimizes virotherapy in glioblastoma and depends on CD4 T-cell activation	<b>Teresa Nguyen</b>
21-A-2905-AACR: Poster Session – Novel Antitumor Agents	1247: Targeting neddylation in combination with cytotoxic chemotherapy for the treatment of renal medullary carcinoma	<b>Daniel Shapiro, M.D.</b>
21-A-3644-AACR: Poster Session – Immune Mechanisms Invoked by Therapies	1656: Effects of chemotherapy on activation of the STING signaling pathway and enhancing immunotherapy responses in colorectal cancer	<b>Rajat Bhattacharya, Ph.D.</b>

<p>21-A-3880-AACR: Poster Session – Immunomodulatory Agents and Interventions</p>	<p>1748: Armed oncolytic adenovirus expressing the positive immune checkpoint OX40L for gastric cancer therapy</p>	<p><b>Ashley Ossimetha</b></p>
<p>21-A-4116-AACR: Poster Session – Adoptive Cell Therapy</p>	<p>1492: Chimeric antigen receptor (CAR) T cell donor dependent dysfunction modulation with activation of autophagy and inhibition of trogocytosis</p>	<p><b>Jiyong Liang, Ph.D.</b></p>
<p>21-A-4227-AACR: Poster Session – Metabolic Pathways</p>	<p>2338: The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment</p>	<p><b>Erika Suzuki, Ph.D.</b></p>
<p>21-A-4499-AACR: Poster Session – Microbiome</p>	<p>2909: Tumor microbiota profiles are associated with molecular subtype and survival in colorectal cancer patients</p>	<p><b>Fangyu Li</b></p>
<p>21-A-4535-AACR: Poster Session – Invasion and Metastasis 2</p>	<p>2884: Wnt11 dictates the patterns and latency of pulmonary micrometastatic disease in pancreatic cancer</p>	<p><b>Eileen Donovan</b></p>
<p>21-A-4607-AACR: Poster Session – Role of the Microenvironment in Therapeutic Response</p>	<p>1440: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell response</p>	<p><b>Chi Lam Au Yeung, Ph.D.</b></p>
<p>21-A-4627-AACR: Poster Session – Combination Immunotherapies</p>	<p>1579: Oncolytic adenovirus Delta-24-RGDOX collaborates with adoptive cell therapy to sustain anti-tumor immunity</p>	<p><b>Hong Jiang, Ph.D.</b></p>
<p>21-A-4643-AACR: Poster Session – microRNAs and Other Noncoding RNAs</p>	<p>2378: Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the beneficial effects of exercise</p>	<p><b>Prince Jeyabal, Ph.D.</b></p>

<p>21-A-3640-AACR: Poster Session – Vaccines</p>	<p>1912: Evasion of neutralizing antibodies and enhanced anti-tumor effects of hexon-modified Delta-24-RGD oncolytic adenovirus</p>	<p><b>Dong Ho Shin</b></p>
<p>21-A-1876-AACR: Poster Session – Biomarkers Predictive of Therapeutic Benefit</p>	<p>384: Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer\</p>	<p><b>Bingnan Zhang, M.D.</b></p>
<p>21-A-2182-AACR: Poster Session – Tumor-Immune System Interactions</p>	<p>3183: Adrenergic signaling augments cytotoxic T-cell anti-tumor function in p53-deficient head and neck cancer</p>	<p><b>Deborah Silverman</b></p>
<p>21-A-2648-AACR: Poster Session – Metabolic Pathways</p>	<p>2335: Targeting MYC-enhanced glycolysis in small cell lung cancer</p>	<p><b>Kasey Cargill</b></p>
<p>21-A-2708-AACR: Poster Session – Drug Resistance in Molecular Targeted Therapies</p>	<p>1105: Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC</p>	<p><b>Ismail Meraz, Ph.D.</b></p>
<p>21-A-3517-AACR: Poster Session – Immune Cells in the Tumor Microenvironment</p>	<p>2749: The unique tumor microenvironment of clear cell ovarian carcinoma</p>	<p><b>Han Cun, M.D.</b></p>
<p>21-A-3624-AACR: Poster Session – Immune Response to Therapies</p>	<p>518: Immunogenomic correlates of response to combination immune checkpoint blockade in advanced sarcoma</p>	<p><b>Akash Mitra</b></p>
<p>21-A-3840-AACR: Poster Session – Immune Monitoring/Clinical Correlates</p>	<p>1670: Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer</p>	<p><b>Cara Haymaker, Ph.D.</b></p>

<p><b>21-A-4131-AACR: Poster Session –</b> Pediatric Cancer: Basic Science</p>	<p>3053: Armed oncolytic virus for treatment of pediatric diffuse intrinsic pontine glioma</p>	<p><b>Sumit Gupta</b></p>
<p><b>21-A-1579-AACR: Poster Session –</b> Stem Cell Biology</p>	<p>3081: Secretory human ribonuclease 1 functions as Eph receptor A4 ligand to promote breast tumor initiation</p>	<p><b>Ying-Nai Wang, Ph.D.</b></p>
<p><b>21-A-2067-AACR: Poster Session –</b> Cellular Stress Response</p>	<p>2017: Dual targeting of glutathione-GPX4 nexus and mitochondrial protease CLPP causes synergistic anti-leukemia effects in acute myeloid leukemia (AML).</p>	<p><b>Hiroki Akiyama, Ph.D.</b></p>
<p><b>21-A-3805-AACR: Poster Session –</b> Angiogenesis</p>	<p>2652: The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis</p>	<p><b>Mark Kim</b></p>
<p><b>21-A-3938-AACR: Poster Session –</b> Preclinical Prevention, Early Detection, and Interception</p>	<p>2589: Gene signature of fluvastatin resistance for prevention of breast cancer and predicting resistance to statins</p>	<p><b>Anjana Bhardwaj, Ph.D.</b></p>
<p><b>21-A-4404-AACR: Poster Session –</b> Mouse Models of Human Cancer</p>	<p>2963: A novel uterine leiomyosarcoma mouse model</p>	<p><b>Kwong-Kwok Wong, Ph.D.</b></p>
<p><b>21-A-2484-AACR: Poster Session –</b> Cell Cycle Mechanisms of Anticancer Drug action</p>	<p>974: Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification</p>	<p><b>Siqing Fu, M.D., Ph.D.</b></p>

<b>ON-DEMAND PRESENTATIONS</b>		
ADT07.OD – Proton Therapy and FLASH Irradiation	Using proton therapy to improve systemic immune responses	<b>James Welsh, M.D.</b>
ADT10.OD – Management of Toxicity of Immune Cell Therapy	Grading and management of cytokine release syndrome	<b>Elizabeth Shpall, M.D.</b>
ADT10.OD – Management of Toxicity of Immune Cell Therapy	Emerging strategies for mitigating IEC toxicities	<b>Sattva Neelapu, M.D.</b>
AOS08.OD – Advances in Endometrial Cancer	Preclinical models of endometrial cancer: Opportunities in immunotherapy and prevention	<b>Melinda Yates, Ph.D.</b>
AOS10.OD – Diffuse Large B-Cell Lymphoma	Determinants of response, resistance and toxicity following CD19 CAR T-cell therapy	<b>Michael Green, Ph.D.</b>
AOS11.OD – Targeting Signaling Pathways in Colorectal Cancer	Adaptive responses to targeted therapy in colorectal cancer	<b>Scott Kopetz, M.D., Ph.D.</b>
LE01 – AACR Gertrude B. Elion Cancer Research Award Lecture	Interplay between ethnicity and biology in response to checkpoint inhibition among patients with unresectable acral melanoma	<b>Kaysia Ludford, M.D.</b>
SS06.OD – AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Cancer	From the clinic to the lab: Investigating mechanisms of response and resistance to immune checkpoint therapy in RCC	<b>Padmanee Sharma, M.D., Ph.D.</b>

SY05.OD: Artificial Intelligence in Cancer Imaging	Quantitative imaging of pancreatic cancer from macroscopic to microscopic scales	<b>Eugene Koay, M.D., Ph.D.</b>
SS08.OD – AACR-ONS Special Session: Symptom Science	Chemobrain, accelerated aging, and peripheral neuropathy as a result of chemotherapy: Mechanisms and treatment	<b>Cobi Heijnen, Ph.D.</b>
SY13.OD – Neoadjuvant Immunotherapy for Melanoma and Other Cancers	Neoadjuvant immunotherapy for operable non-small cell lung cancer: Lessons learned and current challenges	<b>Tina Cascone, M.D., Ph.D.</b>
SY29.OD – The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy	The tumor microbiome of pancreatic cancer long-term survivors	<b>Florencia McAllister, M.D.</b>
SY30.OD – Engineering and Modulating Natural Killer (NK) Cells for Cancer Immunotherapy	CAR NK cells: A drive to the future of cell therapy	<b>Katy Rezvani, M.D., Ph.D.</b>
SY33.OD – Alternative DNA Repair Pathways and Their Drug Targets	Targeting DNA repair pathways in the era of immunotherapy	<b>Lauren Byers, M.D.</b>
SY37.OD – Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy	<b>Han Liang, Ph.D.</b>
SY40.OD – Matrix, Exosomes, and TME Cells in the Metastatic Niche	Blocking brain-infiltrating immunosuppressive neutrophils deters brain metastases	<b>Dihua Yu, M.D., Ph.D.</b>



SY41.OD – The Microbiome in Cancer Therapy: Hype or Hope?	The microbiome and cancer: Minimizing the hype and illuminating the hope	<b>Jennifer Wargo, M.D.</b>
SY45.OD – Implications of Clonal Hematopoiesis in Human Health	Clonal hematopoiesis as a premalignant state	<b>Koichi Takahashi, M.D.</b>

<b>LIVE PANELS</b>		
<b>Monday, April 12</b>		
<b>10:00-10:30 a.m. EDT</b>	SS08.DISC – Panel AACR-ONS Special Session: Symptom Science	<b>Cobi Heijnen, Ph.D.</b>
<b>Tuesday, April 13</b>		
<b>10:00-10:30 a.m. EDT</b>	AOS11.DISC – Panel Targeting Signaling Pathways in Colorectal Cancer	<b>Scott Kopetz, M.D., Ph.D.</b>
<b>1:30–2:00 p.m. EDT</b>	AOS08.DISC – Panel Advances in Endometrial Cancer	<b>Melinda Yates, Ph.D.</b>

<b>1:30-2:00 p.m. EDT</b>	<b>SY30.DISC – Panel</b> Engineering and Modulating Natural Killer (NK) Cells for Cancer Immunotherapy	<b>Katy Rezvani, M.D., Ph.D.</b>
<b>2:30-3:00 p.m. EDT</b>	<b>SS06.DISC – Panel</b> AACR-ASCO Joint Session: Targets in the Treatment of Renal Cell Carcinoma	<b>Padmanee Sharma, M.D., Ph.D.</b>
<b>Wednesday, April 14</b>		
<b>10:00-10:30 a.m. EDT</b>	<b>SY40.DISC – Panel</b> Matrix, Exosomes, and TME Cells in the Metastatic Niche	<b>Dihua Yu, M.D., Ph.D.</b>
<b>10:00-10:30 a.m. EDT</b>	<b>SY41.DISC – Panel</b> The Microbiome in Cancer Therapy: Hype or Hope?	<b>Jennifer Wargo, M.D.</b>
<b>1:30-2:00 p.m. EDT</b>	<b>AOS10.DISC – Panel</b> Diffuse Large B-Cell Lymphoma	<b>Michael Green, Ph.D.</b>
<b>1:30-2:00 p.m. EDT</b>	<b>SY05.DISC – Panel</b> Artificial Intelligence in Cancer Imaging	<b>Eugene Koay, M.D., Ph.D.</b>
<b>1:30-2:00 p.m. EDT</b>	<b>SY29.DISC – Panel</b> The Tumor Microbiome and Its Role in Oncogenesis and Modulating Therapy Response	<b>Florencia McAllister, M.D.</b>
<b>2:30-3:00 p.m. EDT</b>	<b>SY33.DISC – Panel</b> Alternative DNA Repair Pathways and Their Drug Targets	<b>Lauren Byers, M.D.</b>

## Thursday, April 15

<b>10:00-10:30 a.m. EDT</b>	<b>ADT07.DISC – Panel</b> Proton Therapy and FLASH Irradiation	<b>James Welsh, M.D.</b>
<b>10:00-10:30 a.m. EDT</b>	<b>SY37.DISC – Panel</b> Tumor Hypoxia and Genetic Instability: New Mechanisms and New Targets	<b>Han Liang, Ph.D.</b>
<b>12:30-1:00 p.m. EDT</b>	<b>ADT10.DISC – Panel</b> Management of Toxicity of Immune Cell Therapy	<b>Elizabeth Shpall, M.D.</b>
<b>12:30-1:00 p.m. EDT</b>	<b>SY13.DISC - Panel</b> Neoadjuvant Immunotherapy for Melanoma and Other Cancers	<b>Tina Cascone, M.D., Ph.D.</b>
<b>1:30-2:00 p.m. EDT</b>	<b>SY45.DISC – Panel</b> Implications of Clonal Hematopoiesis in Human Health	<b>Koichi Takahashi, M.D.</b>